Patents by Inventor Yasuhiro Hirata
Yasuhiro Hirata has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11953206Abstract: Provided is a burner of double tube structure including an outer tube and an inner tube. The inner tube includes a tip-side support portion fixed on the outer tube, a base-side support portion fixed on the outer tube, a main body portion supported by the tip-side support portion, bellows interposed between the main body portion and the base-side support portion, and a bulkhead member attached at a position between the tip-side support portion and the base-side support portion. Between an outer peripheral surface of the bulkhead member and an inner peripheral surface of the outer tube, a second gap smaller than a first gap between an outermost peripheral surface of the bellows and the inner peripheral surface of the outer tube is interposed.Type: GrantFiled: September 16, 2022Date of Patent: April 9, 2024Assignee: MITSUBISHI HEAVY INDUSTRIES, LTD.Inventors: Mitsuhiro Karishuku, Satoshi Dodo, Yoshitaka Hirata, Tomohiro Asai, Shohei Yoshida, Yasuhiro Akiyama
-
Publication number: 20230117295Abstract: Provided is a compound that may have a superior CDK12 inhibitory action and is expected to be useful as a prophylactic or therapeutic drug for cancer and the like. A compound represented by the following formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.Type: ApplicationFiled: December 6, 2022Publication date: April 20, 2023Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Koji ONO, Masahiro ITO, Toshio TANAKA, Moriteru ASANO, Takaharu HIRAYAMA, Jun FUJIMOTO, Nobuki SAKAUCHI, Yasuhiro HIRATA, Akinori TOITA, Nao MORISHITA, Hironori KOKUBO, Yasuhiro IMAEDA, Hironobu MAEZAKI, Douglas Robert CARY, Ryo MIZOJIRI, Nobuo CHO, Hiroshi BANNO, Hidekazu TOKUHARA, Yasuyoshi ARIKAWA
-
Patent number: 11584737Abstract: Provided is a compound that may have a superior CDK12 inhibitory action and is expected to be useful as a prophylactic or therapeutic drug for cancer and the like. A compound represented by the following formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.Type: GrantFiled: March 28, 2019Date of Patent: February 21, 2023Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Koji Ono, Masahiro Ito, Toshio Tanaka, Moriteru Asano, Takaharu Hirayama, Jun Fujimoto, Nobuki Sakauchi, Yasuhiro Hirata, Akinori Toita, Nao Morishita, Hironori Kokubo, Yasuhiro Imaeda, Hironobu Maezaki, Douglas Robert Cary, Ryo Mizojiri, Nobuo Cho, Hiroshi Banno, Hidekazu Tokuhara, Yasuyoshi Arikawa
-
Patent number: 11479645Abstract: The resin molded article includes a main body part configured to be mounted to a car body panel, a cantilever-shaped seal part for sealing a gap in the car body panel, and a hollow tubular-shaped seal part. The seal part is in resilient contact with the car body panel in a state of being mounted to the car body panel. The seal part is molded from a thermoplastic elastomer containing 25 wt % or more of an olefin block copolymer. It is preferable that the thermoplastic elastomer also contains a dynamically crosslinked olefin-based elastomer in addition to the olefin block copolymer.Type: GrantFiled: February 9, 2018Date of Patent: October 25, 2022Assignee: TOKAI KOGYO CO., LTD.Inventors: Yoshinori Goto, Yasuhiro Hirata
-
Patent number: 11186565Abstract: Provided is a novel aromatic ring compound which may have a GPR40 agonist activity and a GLP-1 secretagogue action. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof may have a GPR40 agonist activity and a GLP-1 secretagogue action, may be useful for the prophylaxis or treatment of cancer, obesity, diabetes, hypertension, hyperlipidemia, cardiac failure, diabetic complications, metabolic syndrome, sarcopenia and the like, and may afford superior efficacy.Type: GrantFiled: March 29, 2018Date of Patent: November 30, 2021Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Seiji Miwatashi, Yasufumi Miyamoto, Koji Watanabe, Yayoi Nakayama, Yuko Hitomi, Jumpei Aida, Nobuyuki Takakura, Hideki Furukawa, Naoyoshi Noguchi, Yasuhiro Hirata, Kazuaki Takami, Norihito Tokunaga, Tomohiro Okawa, Akito Shibuya, Shizuo Kasai, Toshitake Kobayashi, Tsuyoshi Maekawa
-
Publication number: 20210363130Abstract: Provided is a compound that may have a superior CDK12 inhibitory action and is expected to be useful as a prophylactic or therapeutic drug for cancer and the like. A compound represented by the following formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.Type: ApplicationFiled: March 28, 2019Publication date: November 25, 2021Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Koji ONO, Masahiro ITO, Toshio TANAKA, Moriteru ASANO, Takaharu HIRAYAMA, Jun FUJIMOTO, Nobuki SAKAUCHI, Yasuhiro HIRATA, Akinori TOITA, Nao MORISHITA, Hironori KOKUBO, Yasuhiro IMAEDA, Hironobu MAEZAKI, Douglas Robert CARY, Ryo MIZOJIRI, Nobuo CHO, Hiroshi BANNO, Hidekazu TOKUHARA, Yasuyoshi ARIKAWA
-
Patent number: 10968231Abstract: Provided is a novel aromatic ring compound which may have a GPR40 agonist activity and a GLP-1 secretagogue action. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof may have a GPR40 agonist activity and a GLP-1 secretagogue action, may be useful for the prophylaxis or treatment of cancer, obesity, diabetes, hypertension, hyperlipidemia, cardiac failure, diabetic complications, metabolic syndrome, sarcopenia and the like, and may afford superior efficacy.Type: GrantFiled: March 29, 2018Date of Patent: April 6, 2021Assignees: SCOHIA PHARMA, INC., TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Seiji Miwatashi, Yasufumi Miyamoto, Koji Watanabe, Yayoi Nakayama, Yuko Hitomi, Jumpei Aida, Nobuyuki Takakura, Hideki Furukawa, Naoyoshi Noguchi, Yasuhiro Hirata, Shizuo Kasai, Toshitake Kobayashi, Tsuyoshi Maekawa, Satoshi Sasaki, Shigemitsu Matsumoto
-
Publication number: 20200377509Abstract: Provided is a novel aromatic ring compound which may have a GPR40 agonist activity and a GLP-1 secretagogue action. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof may have a GPR40 agonist activity and a GLP-1 secretagogue action, may be useful for the prophylaxis or treatment of cancer, obesity, diabetes, hypertension, hyperlipidemia, cardiac failure, diabetic complications, metabolic syndrome, sarcopenia and the like, and may afford superior efficacy.Type: ApplicationFiled: March 29, 2018Publication date: December 3, 2020Applicants: TAKEDA PHARMACEUTICAL COMPANY LIMITED, SCOHIA PHARMA, INCInventors: Seiji MIWATASHI, Yasufumi MIYAMOTO, Koji WATANABE, Yayoi NAKAYAMA, Yuko HITOMI, Jumpei AIDA, Nobuyuki TAKAKURA, Hideki FURUKAWA, Naoyoshi NOGUCHI, Yasuhiro HIRATA, Shizuo KASAl, Toshitake KOBAYASHI, Tsuyoshi MAEKAWA, Satoshi SASAKI, Shigemitsu MATSUMOTO
-
Patent number: 10800754Abstract: Provided is a heterocyclic amide compound that may have a PRS inhibitory action and is expected to be useful as a prophylactic or therapeutic agent for PRS associated diseases and the like including cancer. A compound represented by the following formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.Type: GrantFiled: September 14, 2017Date of Patent: October 13, 2020Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Takaharu Hirayama, Yasuhiro Hirata, Yusuke Tominari, Naoki Iwamura, Yusuke Sasaki, Moriteru Asano, Terufumi Takagi, Masanori Okaniwa, Masato Yoshida, Shinichi Imamura
-
Patent number: 10774083Abstract: Provided is a heterocyclic amide compound that may have a PRS inhibitory action and is expected to be useful as a prophylactic or therapeutic agent for PRS associated diseases and the like including cancer. A compound represented by the following formula (I): wherein a group represented by is a group represented by the following formula (II) or the following formula (III): and other symbols are as described in the DESCRIPTION, or a salt thereof.Type: GrantFiled: September 14, 2017Date of Patent: September 15, 2020Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Takaharu Hirayama, Yasuhiro Hirata, Yusuke Tominari, Naoki Iwamura, Yusuke Sasaki, Moriteru Asano, Terufumi Takagi, Masanori Okaniwa, Shinichi Imamura
-
Publication number: 20200039957Abstract: Provided is a novel aromatic ring compound which may have a GPR40 agonist activity and a GLP-1 secretagogue action. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof may have a GPR40 agonist activity and a GLP-1 secretagogue action, may be useful for the prophylaxis or treatment of cancer, obesity, diabetes, hypertension, hyperlipidemia, cardiac failure, diabetic complications, metabolic syndrome, sarcopenia and the like, and may afford superior efficacy.Type: ApplicationFiled: March 29, 2018Publication date: February 6, 2020Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Seiji MIWATASHI, Yasufumi MIYAMOTO, Koji WATANABE, Yayoi NAKAYAMA, Yuko HITOMI, Jumpei AIDA, Nobuyuki TAKAKURA, Hideki FURUKAWA, Naoyoshi NOGUCHI, Yasuhiro HIRATA, Kazuaki TAKAMI, Norihito TOKUNAGA, Tomohiro OKAWA, Akita SHIBUYA, Shizuo KASAl, Toshitake KOBAYASHI, Tsuyoshi MAEKAWA
-
Patent number: 10519110Abstract: The present invention relates to a compound which can be useful for the treatment or prevention of SPT-related diseases including cancer and congenital diseases associated with sphingolipid accumulation (including Niemann-Pick disease).Type: GrantFiled: October 30, 2018Date of Patent: December 31, 2019Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Yasutomi Asano, Takuto Kojima, Osamu Kurasawa, Tzu-Tshin Wong, Yasuhiro Hirata, Naoki Iwamura, Bunnai Saito, Yuta Tanaka, Ryosuke Arai, Shinichi Imamura, Kazuko Yonemori, Yasufumi Miyamoto, Shuji Kitamura, Osamu Sano
-
Publication number: 20190390021Abstract: The resin molded article includes a main body part configured to be mounted to a car body panel, a cantilever-shaped seal part for sealing a gap in the car body panel, and a hollow tubular-shaped seal part. The seal part is in resilient contact with the car body panel in a state of being mounted to the car body panel. The seal part is molded from a thermoplastic elastomer containing 25 wt % or more of an olefin block copolymer. It is preferable that the thermoplastic elastomer also contains a dynamically crosslinked olefin-based elastomer in addition to the olefin block copolymer.Type: ApplicationFiled: February 9, 2018Publication date: December 26, 2019Applicant: TOKAI KOGYO CO., LTD.Inventors: Yoshinori GOTO, Yasuhiro HIRATA
-
Publication number: 20190359587Abstract: Provided is a heterocyclic amide compound that may have a PRS inhibitory action and is expected to be useful as a prophylactic or therapeutic agent for PRS associated diseases and the like including cancer. A compound represented by the following formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.Type: ApplicationFiled: September 14, 2017Publication date: November 28, 2019Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Takaharu HIRAYAMA, Yasuhiro HIRATA, Yusuke TOMINARI, Naoki IWAMURA, Yusuke SASAKI, Moriteru ASANO, Terufumi TAKAGI, Masanori OKANIWA, Masato YOSHIDA, Shinichi IMAMURA
-
Publication number: 20190241566Abstract: Provided is a heterocyclic amide compound that may have a PRS inhibitory action and is expected to be useful as a prophylactic or therapeutic agent for PRS associated diseases and the like including cancer. A compound represented by the following formula (I): wherein a group represented by is a group represented by the following formula (II) or the following formula (III): and other symbols are as described in the DESCRIPTION, or a salt thereof.Type: ApplicationFiled: September 14, 2017Publication date: August 8, 2019Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Takaharu HIRAYAMA, Yasuhiro HIRATA, Yusuke TOMINARI, Naoki IWAMURA, Yusuke SASAKI, Moriteru ASANO, Terufumi TAKAGI, Masanori OKANIWA, Masato YOSHIDA, Takashi ICHIKAWA, Shinichi IMAMURA
-
Publication number: 20190062274Abstract: The present invention relates to a compound which can be useful for the treatment or prevention of SPT-related diseases including cancer and congenital diseases associated with sphingolipid accumulation (including Niemann-Pick disease).Type: ApplicationFiled: October 30, 2018Publication date: February 28, 2019Inventors: Yasutomi ASANO, Takuto KOJIMA, Osamu KURASAWA, Tzu-Tshin WONG, Yasuhiro HIRATA, Naoki IWAMURA, Bunnai SAITO, Yuta TANAKA, Ryosuke ARAI, Shinichi IMAMURA, Kazuko YONEMORI, Yasufumi MIYAMOTO, Shuji KITAMURA, Osamu SANO
-
Patent number: 10189785Abstract: The present invention relates to a compound which can be useful for the treatment or prevention of SPT-related diseases including cancer and congenital diseases associated with sphingolipid accumulation (including Niemann-Pick disease).Type: GrantFiled: April 19, 2016Date of Patent: January 29, 2019Assignee: Takeda Pharmaceuticals Company LimitedInventors: Yasutomi Asano, Takuto Kojima, Osamu Kurasawa, Tzu-Tshin Wong, Yasuhiro Hirata, Naoki Iwamura, Bunnai Saito, Yuta Tanaka, Ryosuke Arai, Shinichi Imamura, Kazuko Yonemori, Yasufumi Miyamoto, Shuji Kitamura, Osamu Sano
-
Publication number: 20180170874Abstract: The present invention relates to a compound which can be useful for the treatment or prevention of SPT-related diseases including cancer and congenital diseases associated with sphingolipid accumulation (including Niemann-Pick disease).Type: ApplicationFiled: April 19, 2016Publication date: June 21, 2018Inventors: Yasutomi ASANO, Takuto KOJIMA, Osamu KURASAWA, Tzu-Tshin WONG, Yasuhiro HIRATA, Naoki IWAMURA, Bunnai SAITO, Yuta TANAKA, Ryosuke ARAI, Shinichi IMAMURA, Kazuko YONEMORI, Yasufumi MIYAMOTO, Shuji KITAMURA, Osamu SANO
-
Patent number: 9957251Abstract: The present invention provides a heterocyclic compound having a CDK8 and/or CDK19 inhibitory effect. The present invention provides a compound represented by formula (I) (in the formula, the symbols are as defined in the description) or a salt thereof.Type: GrantFiled: April 16, 2015Date of Patent: May 1, 2018Assignee: Takeda Pharmaceutical Company LimitedInventors: Takaharu Hirayama, Jun Fujimoto, Douglas Robert Cary, Masanori Okaniwa, Yasuhiro Hirata
-
Patent number: 9776962Abstract: Provided is a novel aromatic ring compound having a GPR40 agonist activity and a GLP-1 secretagogue action. A compound represented by the formula: wherein each symbol is as described in the DESCRIPTION, or a salt thereof has a GPR40 agonist activity and a GLP-1 secretagogue action, is useful for the prophylaxis or treatment of cancer, obesity, diabetes, hypertension, hyperlipidemia, cardiac failure, diabetic complications, metabolic syndrome, sarcopenia and the like, and affords superior efficacy.Type: GrantFiled: August 8, 2014Date of Patent: October 3, 2017Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Jumpei Aida, Yayoi Yoshitomi, Yuko Hitomi, Naoyoshi Noguchi, Yasuhiro Hirata, Hideki Furukawa, Akito Shibuya, Koji Watanabe, Yasufumi Miyamoto, Tomohiro Okawa, Nobuyuki Takakura, Seiji Miwatashi